share_log

S-3: Registration statement for specified transactions by certain issuers

S-3: Registration statement for specified transactions by certain issuers

S-3：特定交易注册声明
美股SEC公告 ·  2024/11/04 06:19

Moomoo AI 已提取核心信息

Aclarion, Inc., a Delaware-based healthcare technology company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on November 1, 2024. The registration pertains to the issuance of up to 27,515,153 shares of common stock, which includes shares issuable upon conversion of Series C Convertible Preferred Stock and upon the exercise of warrants. The registration statement includes a prospectus that provides detailed information about the offering, the company's business, financial statements, and the risks involved in investing in the company. Aclarion has not specified the timing of the sale of these securities, indicating that the sale may occur from time to time after the effective date of the registration statement. The company will not receive any proceeds from the sale of shares by the selling stockholders but may receive proceeds from the exercise of the warrants. The registration statement also includes provisions for indemnification of directors and officers, details on the company's capital stock, and the legal and expert opinions related to the offering.
Aclarion, Inc., a Delaware-based healthcare technology company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on November 1, 2024. The registration pertains to the issuance of up to 27,515,153 shares of common stock, which includes shares issuable upon conversion of Series C Convertible Preferred Stock and upon the exercise of warrants. The registration statement includes a prospectus that provides detailed information about the offering, the company's business, financial statements, and the risks involved in investing in the company. Aclarion has not specified the timing of the sale of these securities, indicating that the sale may occur from time to time after the effective date of the registration statement. The company will not receive any proceeds from the sale of shares by the selling stockholders but may receive proceeds from the exercise of the warrants. The registration statement also includes provisions for indemnification of directors and officers, details on the company's capital stock, and the legal and expert opinions related to the offering.
Aclarion公司是一家总部位于特拉华州的医疗科技公司，于2024年11月1日向证券交易委员会（SEC）提交了S-3表格注册声明。该注册涉及发行高达27,515,153股普通股，其中包括转换为C系列可转换优先股和行使认股权所发行的股票。注册声明包括一份招股说明书，详细介绍了该公司的业务、基本报表以及投资于该公司所涉及的风险。Aclarion未指定这些证券的销售时间，表明销售可能在注册声明生效日期后的任何时间发生。公司将不会从股东出售的股票销售中获得任何收益，但可能会从行使认股权中获得收益。注册声明还包括对董事和高管的赔偿条款、关于公司资本股的细节，以及与该发行相关的法律和专家意见。
Aclarion公司是一家总部位于特拉华州的医疗科技公司，于2024年11月1日向证券交易委员会（SEC）提交了S-3表格注册声明。该注册涉及发行高达27,515,153股普通股，其中包括转换为C系列可转换优先股和行使认股权所发行的股票。注册声明包括一份招股说明书，详细介绍了该公司的业务、基本报表以及投资于该公司所涉及的风险。Aclarion未指定这些证券的销售时间，表明销售可能在注册声明生效日期后的任何时间发生。公司将不会从股东出售的股票销售中获得任何收益，但可能会从行使认股权中获得收益。注册声明还包括对董事和高管的赔偿条款、关于公司资本股的细节，以及与该发行相关的法律和专家意见。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Performant Healthcare
    PHLT
    -- 3.000
    SHL Telemedicine
    SHLT
    -- 1.950
    Simulations Plus
    SLP
    -- 24.290
    Mangoceuticals
    MGRX
    -- 2.380
    Forian
    FORA
    -- 2.000
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日